SEC Filings
ADMA Raises Its Profit Floor As ASCENIV Sales Climb 31% And BIVIGAM Revenue Drops To $15.4 Million
The plasma-drug maker held its revenue outlook but lifted minimum 2026 adjusted profit targets after gross margin reached 71%.
ADMA
ADMA Biologics (ADMA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
ADMA's Ascenev Is Up 31%, But CEO Says Secondary Immune Deficiency Growth Is 'Slower' Than Hoped
ADMA raised its minimum profit guidance while Bivigam revenue fell to $15.4 million from $19.4 million in the second quarter.
Earnings
ADMA's Profit Jumps On One Drug While A $125 Million Revolver Draw Funds Buybacks
ASCENIV lifted third-quarter net income to $49.9 million, but long-term debt reached $191.6 million and a securities suit advanced.